CompanySema4 Holdings Corp.
United States of America
Sema4 is a patient-centered, health intelligence company with a mission to use artificial intelligence, or AI, and machine learning to enable personalized medicine for all. The Company's integrated information platform leverages longitudinal patient data, AI-driven predictive modeling, and genomics in combination with other molecular and high-dimensional data in their efforts both to deliver better outcomes for patients and to transform the practice of medicine, including how disease is diagnose...
Private/Public:
public
Phone:(800) 298-6470
Address:333 Ludlow Street, North Tower, 8th Floor
Stamford, Connecticut 06902, United States of America
Top Services
United States of America
- (14.Jun.2022) Sema4 Announces Chief Financial Officer Transition Plan
- (01.Jun.2022) Avera Health and Sema4 Announce Data-Driven Study to Advance Cancer Treatment Across the Avera Service Area
- (12.May.2022) Sema4 Reports First Quarter 2022 Financial Results and Business Highlights
- (04.May.2022) Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- (02.May.2022) Sema4 Closed a Private Placement Financing of $200 Million
- (02.May.2022) Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of Its Diagnostic and Clinical Data Platforms
- (06.Apr.2022) Sema4 Achieves HITRUST CSF Certification
- (05.Apr.2022) Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
- (16.Mar.2022) Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities
- (14.Mar.2022) Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
- (08.Mar.2022) Sema4 Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022
- (22.Feb.2022) Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
- (10.Jan.2022) Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021
- (15.Nov.2021) Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights
- (16.Aug.2021) Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights
- (22.Jul.2021) Sema4 Closes Transaction With CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company
- (02.Jul.2021) CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination